|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|US10328029||CYCLE PHARMS LTD||Pharmaceutical composition|| |
(11 years from now)
Market Authorisation Date: 26 July, 2017
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic